X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BTA798 (Vapendavir) has shown promising preclinical and clinical data demonstrating effective control of certain respiratory viruses, can potentially be used to treat epidemic hand, foot and mouth disease (HFMD) and HRV infection in COPD Patients.
Lead Product(s): Vapendavir
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BTA798
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
With the newly announced AViDD award, Altesa options include relevant compounds advanced by DRIVE stemming from Emory’s Antiviral Countermeasure Development Center.
Lead Product(s): Antiviral Therapeutic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $52.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 25, 2022
Details:
The collaboration includes a license to ALT-2023, a broadly active nucleoside analogue that is late stage preclinical development, as well as options to additional compounds addressing RNA viruses.
Lead Product(s): ALT-2023
Therapeutic Area: Infections and Infectious Diseases Product Name: ALT-2023
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Drug Innovation Ventures at Emory
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
